Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.6K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.6K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

886
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
886
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

958
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
958
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

335
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
335
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

1.6K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and Efficacy of Once-Daily Oral Paltusotine in Acromegaly: ACROBAT Advance Open-Label Extension Up to 4 Years.

The Journal of clinical endocrinology and metabolism·2026
Same author

Reassuring long-term data on efficacy and safety of pegvisomant monotherapy in a large series of patients with acromegaly.

Pituitary·2026
Same author

Impact of Osilodrostat on Health-Related Quality of Life in Cushing's Disease: Analysis of Patient-Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials.

Clinical endocrinology·2026
Same author

Differential expression of POMC-processing genes in corticotroph tumors.

Endocrine oncology (Bristol, England)·2026
Same author

Consensus on acromegaly complications: an update.

Pituitary·2026
Same author

Adenoma receptors and histologic characteristics determining management outcomes.

The Journal of clinical endocrinology and metabolism·2026

Related Experiment Video

Updated: Jan 14, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

19.5K

Medical Therapies for Acromegaly.

Mônica R Gadelha1, Leandro Kasuki2, Carolina Aloan3

  • 1Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Neuroendocrine Unit, Instituto Estadual do Cérebro Paulo Niemeyer, Secretaria Estadual de Saúde, Rio de Janeiro, Neuropathology and Molecular Genetics Laboratory, Secretaria Estadual de Saúde, R. Prof. Rodolpho Paulo Rocco, 255 - Cidade Universitária, Rio de Janeiro - RJ, 21941-617, Brazil.

Endocrinology and Metabolism Clinics of North America
|October 23, 2025
PubMed
Summary

Surgery is the primary treatment for acromegaly, but many patients need additional medical therapy. Current treatments are not always effective, prompting research into new drugs.

Keywords:
AcromegalyDopamine agonistGH receptor antagonistNew drugsSomatostatin receptor ligand

More Related Videos

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.2K
Author Spotlight: Investigating the Mechanism of Action of Acupotomy in Treating Knee Osteoarthritis
08:40

Author Spotlight: Investigating the Mechanism of Action of Acupotomy in Treating Knee Osteoarthritis

Published on: October 20, 2023

1.7K

Related Experiment Videos

Last Updated: Jan 14, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

19.5K
An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.2K
Author Spotlight: Investigating the Mechanism of Action of Acupotomy in Treating Knee Osteoarthritis
08:40

Author Spotlight: Investigating the Mechanism of Action of Acupotomy in Treating Knee Osteoarthritis

Published on: October 20, 2023

1.7K

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Acromegaly is a rare hormonal disorder caused by excess growth hormone.
  • Surgery is the initial treatment, but 50% of patients require further medical management.
  • Current therapies include somatostatin receptor ligands, dopamine agonists, and growth hormone receptor antagonists.

Purpose of the Study:

  • To review the current medical management of acromegaly.
  • To discuss emerging therapeutic strategies and future directions in acromegaly treatment.

Main Methods:

  • Literature review of current acromegaly treatments.
  • Analysis of treatment efficacy and patient outcomes.
  • Exploration of ongoing research and novel drug development.

Main Results:

  • Despite available treatments, many acromegaly patients experience uncontrolled disease or persistent symptoms.
  • Existing therapies have limitations in efficacy and quality of life improvement for some patients.
  • New drugs with novel mechanisms and administration routes are under investigation.

Conclusions:

  • Current medical therapies for acromegaly are insufficient for a significant patient subset.
  • Further research is essential to develop more effective treatments for acromegaly.
  • Future acromegaly management will likely involve novel pharmacological approaches.